Abstract Technetium-99 conjugated with methylene diphosphonate ( 99 Tc-MDP) is a novel bisphosphonate derivative without radioactivity and has been successfully used to treat arthritis in China for years. Since bisphosphonate therapy has the potential to induce bisphosphonaterelated osteonecrosis of the jaw (BRONJ), we examined whether 99 Tc-MDP represents a new class of bisphosphonate for antiresorptive therapy to ameliorate estrogen deficiency-induced bone resorption with less risk of causing BRONJ. We showed that 99 Tc-MDP-treated, ovariectomized (OVX) mice had significantly improved bone mineral density and trabecular bone volume in comparison to the untreated OVX group by inhibiting osteoclasts and enhancing osteogenic differentiation of bone marrow mesenchymal stem cells. To determine the potential of inducing BRONJ, 99 Tc-MDP/dexamethasone (Dex) or zoledronate/Dex was administered into C57BL/6J mice via the tail vein, followed by extraction of maxillary first molars. Interestingly, 99 Tc-MDP treatment showed less risk to induce osteonecrosis in the maxillary bones compared to zoledronate treatment group, partially because 99 Tc-MDP neither suppressed adaptive regulatory T cells nor activated the inflammatory T-helper-producing interleukin-17 cells. Taken together, our findings demonstrate that 99 Tc-MDP therapy may be a promising approach in the treatment of osteoporosis with less risk of causing BRONJ.
mineral density (BMD) [1] [2] [3] [4] [5] . Although bisphosphonate therapy has been widely used in clinics, concerns have been raised by the emergence of side effects such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). Currently, there is no appropriate therapy available in clinics because we still do not understand the underlying pathophysiological mechanism of BRONJ [1, [6] [7] [8] . By establishing a BRONJ mouse model, we recently found that administration of zoledronate causes BRONJ-like disease in mice, in part by suppressing adaptive regulatory T cells (Tregs), while at the same time activating the inflammatory T-helper-producing interleukin-17 cells (Th17) [7] . These results suggest that BRONJ is a disease associated with immune dysfunction triggered by administration of bisphosphonate and trauma. Therefore, it is critical to develop appropriate drugs with the capacity for ameliorating the osteoporotic phenotype with minimal risk of inducing BRONJ.
Technetium-99 conjugated with methylene diphosphonate ( 99 Tc-MDP) is a patented anti-inflammatory drug, and it has been used as a safe treatment for rheumatoid arthritis (RA) and ankylosing spondylitis in China since 1997 [9] . Since 99 Tc-MDP is a radioactivity-safe decay product of 99m Tc-MDP that has been widely used in bone scintigraphy as a radioactive agent with no significant adverse effects in clinical use. It has been proved that 99 Tc-MDP treatment can inhibit macrophage infiltration together with downregulation of proinflammatory cytokines, including TNF-a and IL1-b, ICAM-1, and MMPs [9, 10] . Since 99 Tc-MDP has both potential antiresorptive effects as a bisphosphonate derivative and anti-inflammatory effects by inhibiting proinflammatory cytokines, it is reasonable to hypothesize that 99 Tc-MDP might have a therapeutic effect for osteoporosis. Also, it is important to evaluate whether 99 Tc-MDP treatment affects the balance between Tregs and Th17 since Treg/ Th17 cell imbalance is an important contributing factor for BRONJ [7] . In this study, we demonstrate that administration of 99 Tc-MDP results in improvement of BMD in ovariectomy (OVX)-induced osteoporotic mice by inhibiting osteoclasts and enhancing osteogenesis of bone marrow mesenchymal stem cells (BMMSCs). In contrast to zolendronate, we also show that 99 Tc-MDP treatment neither increases Th17 levels nor decreases Treg levels, thus avoiding the onset of BRONJ in a mouse model.
Materials and Methods

OVX and BRONJ Mouse Models
Female C3H/HeJ strain mice (8 weeks old) were purchased from Jackson Laboratory (Bar Harbor, ME). OVX mice were generated as described previously [11] , and age-matched C3H/HeJ mice receiving a sham operation served as controls (n = 8). In experimental groups (n = 11), 99 Tc-MDP (Yunke, Chengdu, Sichuan, People's Republic of China; 62.5 lg/kg, once per week) or zoledronate (Zometa; Novartis Oncology, East Hanover, NJ; 62.5 lg/kg, once per week) was administrated intravenously 2 weeks post-OVX for 2 weeks. Mice were killed 5 weeks after OVX.
To generate the BRONJ mouse model, C57BL/6J mice (Jackson Laboratory) received intravenous zoledronate (125 lg/kg, twice per week) with or without dexamethasone (Dex) (Sigma-Aldrich, St. Louis, MO; 5 mg/kg, twice per week, n = 11 and 10, respectively). Due to the different metabolic rates between mice and humans, a body surface area calculation method was recommended by the FDA (http://www.fda.gov/downloads/Drugs/GuidanceCom plianceRegulatoryInformation/Guidances/ucm078932.pdf). The dosage used in mice needs to be at least 12 times more than that in humans.
Therefore, we used a 12-13 times higher dosage of zoledronate to induce BRONJ in mice. Mice were injected with 99 Tc-MDP (125 lg/kg, twice each week) with or without Dex (5 mg/kg, twice each week, n = 10) via the tail vein. One week after injection, maxillary first molars were extracted under deep anesthesia by i.p. injection of ketamine (Ketaject, 95 mg/kg; Phoenix, St. Joseph, MO) and xylazine (Xylaject, 5 mg/kg; Phoenix). Two weeks after tooth extraction, intact maxillas were harvested en bloc. A total of six doses of zoledronate/Dex and 99 Tc-MDP/Dex were administered for the 2-week follow-up groups. Untreated mice with tooth extraction were used as controls.
All animal experiments were performed under institutionally approved protocols for animal research at the University of Southern California (USC 11141, 10941, and 11327).
Antibodies and Reagents
Anti-alkaline phosphatase (ALP) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-b-actin antibody was purchased from Sigma-Aldrich. Purified mouse anti-peroxisome proliferator-activated receptor c (PPARc) IgG MAb and goat anti-lipoprotein lipase (LPL) IgG were from Santa Cruz Biotechnology. APC-conjugated anti-CD4, PE-conjugated anti-FoxP3, and PE-conjugated anti-IL17 antibodies were purchased from eBioscience (San Diego, CA).
Enzyme-Linked Immunosorbent Assay
Serum markers of bone turnover, including receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG), were measured using enzymelinked immunosorbent assay (ELISA) kits purchased from R&D System (Minneapolis, MN) according to the manufacturer's instructions.
MicroCT Analysis
Femurs were harvested and analyzed by the Inveon micro-CT system (Siemens, Munich, Germany). Cross-sectional volumetric BMD was measured at the right femur middiaphysis with a density phantom. Specimens were scanned with the following parameters: 14 lm resolution, 80 kV voltage, 80 lA current, 2,730 ms exposure time. Using 3-dimensional images, a region of interest in secondary spongiosa was manually drawn near the endocortical surface and trabecular thickness (Tb.Th, mm), bone volume/ total volume (BV/TV, %), and bone trabecular number (Tb.N) were assessed as cancellous bone morphometric parameters.
Bone Histological and Histomorphometric Analyses
For histological and histomorphometric analyses, femurs and tibias were fixed with 4 % paraformaldehyde after death. Samples were decalcified with 10 % EDTA (pH 8.0), embedded in paraffin, and stained with hematoxylin and eosin (H&E) for sections, followed by calculation of trabecular bone volume percentage using ImageJ software (http://rsbweb.nih.gov/ij/download.html) in the area of interest. Trabecular bone only was analyzed by not including sections within two fields from either the growth plate or the cortices. Care was taken to analyze the same, standard site in every animal. At least five fields (1 9 1 mm area of bone) per sample were counted. Tartrate-resistant acid phosphate (TRAP) staining was performed according to a previous report [12] . For quantification of bone resorption in the bones, five representative images were analyzed using ImageJ software. The results are shown as osteoclastic surface per millimeter bone surface (Oc.S/BS). All parameters were assessed by a single, experienced technician, blinded to the treatment group of the mice, as previously described [13, 14] . Kidney, liver, and bladder were also harvested from each mouse, and H&E staining was used to detect whether there was any pathological change. Histological analysis in the BRONJ model was performed as described previously [7] .
Mouse BMMSC and Jaw Bone MSC Culture Bone marrow cells were flushed out from the bone cavity of femurs and tibias with 2 % heat-inactivated fetal bovine serum (FBS; Equitech-Bio, Kerrville, TX) in PBS. A single-cell suspension was obtained by passing through 70-lm cell strainers (BD Bioscience, Franklin Lakes, NJ). Jaw bone MSCs (JBMSCs) were isolated from mouse mandibles according to our previous report [15] . Briefly, both attached soft tissues and teeth were removed from the mandibles, and all nucleated cells from mandibles were obtained by digestion with 3 mg/mL collagenase type I (Worthington Biochem, Lakewood, NJ) and 4 mg/mL dispase II (Roche Diagnostic, Indianapolis, IN) for 60 min at 37°C. Both BMMSCs and JBMSCs were seeded and cultured with alpha-minimum essential medium (a-MEM) (Invitrogen, Carlsbad, CA) supplemented with 20 % FBS, 2 mM L-glutamine (Invitrogen), 55 lM 2-mercaptoethanol (Invitrogen), 100 U/mL penicillin, and 100 lg/mL streptomycin (Invitrogen). Attached cells were cultured for 16 days. To confirm MSC characteristics, we used flowcytometric analysis to show that these cells were positive for CD73, CD90, CD105, CD146, CD166, Sca-1, and SSEA-4 but negative for CD11b, CD31, CD34, and CD45.
CFU-F and BrdU Incorporation Assays
P1 MSCs were seeded in T-25 culture flasks (Nalgene Nunc, Rochester, NY). After 16 days, flasks were stained with a mixture of 0.1 % toluidine blue (Merck, Darmstadt, Germany) and 2 % paraformaldehyde (Merck) solution. Colonies containing [50 cells were counted as singlecolony clusters. Total colony numbers were counted per flask by light microscopy. The CFU-F number was repeated in five independent samples per experimental group.
P1 cells (1 9 10 4 /well) were seeded on two-well chamber slides (Nalgene Nunc) for 1-2 days, incubated with BrdU reagent (1:100, Invitrogen) for 24 h, and stained with a BrdU staining kit (Invitrogen), following the manufacturer's instructions. Finally, cells were lightly stained with hematoxylin solution (Invitrogen). To quantify cell proliferation capacity, we used 10 representative images to calculate BrdU-positive nuclei numbers. Cell proliferation was shown as a percentage of BrdU-positive nuclei over total nucleated cells. The BrdU assay was repeated with five independent isolated cells for each experimental group.
Osteogenic and Adipogenic Differentiation Assays
For the in vitro osteogenesis assay, MSCs were cultured to confluence and changed to an osteoinductive medium containing 2 mM b-glycerophosphate (Sigma-Aldrich), 100 mM L-ascorbic acid 2-phosphate (Wako Pure Chemical Industries, Osaka, Japan), and 10 nM Dex (Sigma-Aldrich). After 4 weeks of osteoinductive culture, calcium deposits were detected by staining with 1 % alizarin red (Sigma-Aldrich). Mineralized areas were quantified using Image J and shown as a percentage of alizarin red-positive area over total area. For the adipogenic induction assay, MSCs were cultured to confluence and then induced in an adipogenic medium containing 500 lM isobutylmethylxanthine, 60 lM indomethacin, 0.5 lM hydrocortisone, and 10 lM insulin for 1 week. Cultures were stained with 0.3 % oil red O after adipogenic induction. The number of oil red O-positive droplet-containing cells was determined and shown as a percentage of oil red O-positive cells over total cells. Three independent experiments were performed for each assay.
Western Blot Analysis
Total protein was extracted using M-PER mammalian protein extraction reagent (Thermo, Rockford, IL). Twenty micrograms of protein were applied and separated on 4-12 % NuPAGE gel (Invitrogen), followed by transferring to Immobilon TM -P nitrocellulose membranes (Millipore, Bedford, MA). Membranes were blocked with 5 % nonfat dry milk and 0.1 % Tween-20 for 1 h, followed by incubation with the primary antibodies (1:200-1,000 dilution) at 4°C overnight. Horseradish peroxidase-conjugated IgG (Santa Cruz Biotechnology, 1:10,000) was used to treat the membranes for 1 h, followed by enhancement with a SuperSignal Ò West Pico Chemiluminescent Substrate (Thermo). Bands were detected on BIOMAX MR film (Kodak, Rochester, NY). Each membrane was also stripped using a stripping buffer (Thermo) and reprobed with anti-b-actin antibody to quantify the amount of loaded protein.
Flow-Cytometric Analysis of Th17 and Tregs
Cells collected from mouse spleens were treated with ACK lysis buffer (Lonza, Basel, Switzerland) to remove red blood cells. Spleen cells (1 to 2 9 10 6 ) were activated with 5 ng/ mL phorbol 12-myristate 13-acetate (Sigma-Aldrich), 250 ng/mL ionomycin (Sigma-Aldrich), and 1 lg/mL brefeldin A (GolgiPlug, BD Bioscience) for 4 h at 37°C and 5 % CO 2 , followed by incubation with 1 lg of PerCP-conjugated anti-CD4 antibody for 30 min on ice under dark condition. For Treg analysis, another 1 lg of APC-conjugated anti-CD25 was added during the incubation. After cell fixation and permeabilization using the Foxp3 staining buffer kit, cells were stained with 1 lg of PE-conjugated anti-Foxp3 for Tregs and APC-conjugated anti-IFN-c/PE-conjugated anti-IL17 for Th17. Isotype-matched PE-, APC-, or PerCP-conjugated IgGs were used as controls. After washing with PBS/ 0.4 % BSA three times, cells were analyzed using a FACS Calibur flow cytometer (BD Bioscience).
Statistics SPSS 13.0 (SPSS, Inc., Chicago, IL) was used to perform statistical analysis. Significance was assessed by analysis of variance (ANOVA), followed by Tukey's post hoc test. p \ 0.05 was considered significant.
Results
Tc-MDP Administration Ameliorates OVX-Induced BMD Reduction
Since osteoporosis is associated with overactivation of osteoclasts, we hypothesized that 99 Tc-MDP might ameliorate osteoporosis phenotypes by inhibiting osteoclast activity. OVX mice, a reliable animal model for estrogen-deficient osteoporosis [2, 12, 16, 17] , were used to examine the efficacy of 99 Tc-MDP treatment (Fig. 1a) . In terms of bone turnover markers in serum, ELISAs showed that RANKL levels were markedly decreased after 99 Tc-MDP and zoledronate administration, whereas OPG levels were markedly increased compared with the OVX group (Fig. 1b, c) . MicroCT analysis showed that 99 Tc-MDP administration at 2 weeks post-OVX significantly increased BMD, BV/TV, Tb.Th, and Tb.N in comparison to the untreated OVX group, to an extent comparable to zoledronate (Fig. 1d-h ). Histological analysis indicated that trabecular bone structures in 99 Tc-MDP-treated OVX mice were significantly improved (Fig. 1i, j) . Bone resorption was markedly reduced after 99 Tc-MDP treatment in OVX mice, as indicated by a reduction in Oc.S/BS (Fig. 1k) . Moreover, H&E staining showed that 99 Tc-MDP treatment failed to impair kidney, liver, and bladder ( Supplementary  Fig. 2 ), indicating that 99 Tc-MDP administration may not be toxic to OVX mice. These data suggest that 99 Tc-MDP administration provides an effective treatment for OVXinduced osteoporosis by inhibiting bone resorption. 99 
Tc-MDP Administration Increases Osteoblast Activity in OVX Mice
Since osteoporosis is associated with downregulated osteoblast activity, which is caused by the osteogenic deficiency of BMMSCs [12, 18] , we examined whether 99 Tc-MDP administration could elevate the osteogenic ability of BMMSCs in OVX mice. We harvested BMMSCs and JBMSCs from OVX mice with or without 99 Tc-MDP and zoledronate administration, respectively. We found that both drugs reduced CFU-F and proliferation rate in BMMSCs (Fig. 2a, b) and JBMSCs ( Supplementary  Fig. 1a, b) , respectively. In the osteogenic assay, both drugs increased mineralized nodule formation in the BMMSC (Fig. 2c) and JBMSC (Supplementary Fig. 1c ) groups, as measured by alizarin red staining and expression of the osteogenic marker ALP, shown by Western blot analysis (Fig. 2d, Supplementary Fig. 1d ). This indicated that 99 Tc-MDP treatment elevated the osteogenic capacity of MSCs by sacrificing their proliferation rate in OVX mice. On the other hand, both 99 Tc-MDP and zoledronate treatments were able to significantly decrease the adipogenic differentiation capacity of BMMSCs (Fig. 2e) and JBMSCs ( Supplementary Fig. 1e ) derived from OVX mice, as indicated by the decreased number of oil red O-positive cells and reduced expression of the adipogenic genes PPARc and LPL (Fig. 2f, Supplementary Fig. 1f ; p \ 0.05). Osteogenic and adipogenic differentiation capacities between the sham group and the drug-treated groups showed a significant difference (p \ 0.05). 99 
Tc-MDP Administration Diminishes the Risk of BRONJ Onset by Maintaining Balance between Tregs and Th17
Since 99 Tc-MDP administration shows therapeutic effects on ameliorating osteoporotic phenotypes in OVX mice comparable to those of zoledronate-treated OVX mice, we next asked whether 99 Tc-MDP administration could avoid the risk of BRONJ onset. We utilized a BRONJ animal model, as previously described [7] , to test this hypothesis. C57BL/6J mice were i.v.-injected with zoledronate or 99 Tc-MDP (125 lg/kg) and Dex (5 mg/kg) for 1 week before extraction of the first maxillary molar, and the drug treatment continued twice a week until mice were killed (Fig. 3a) . The maxillary bones were evaluated for clinical signs of BRONJ lesions, following the guidelines established by the American Association of Oral and Maxillofacial Surgeons and the American Society for Bone and Mineral Research [19] [20] [21] . Clinical examination revealed an incomplete mucosal healing and open sockets with exposed bone in 20 % of mice treated with zoledronate and 45 % of mice treated with a combination of zoledronate and Dex (Fig. 3b, c) . The finding of BRONJ in these treated mice was confirmed by a histological study that revealed a lack of epithelial lining at the alveolar socket (Fig. 3c) . Moreover, necrotic bone was found adjacent to the area of intense inflammatory infiltrates, suggesting an association between inflammation and tissue necrosis in BRONJ-like disease (Fig. 3c) . In contrast, 100 % of the 99 Tc-MDP-treated mice, either with or without Dex, showed complete epithelial coverage, which was confirmed by histological study (Fig. 3b, c) . These data indicated that Tc-MDP (TC) or zoledronate (ZO) treatment. b, c RANKL levels in peripheral blood were markedly decreased in both TC-and ZO-treated groups compared with the OVX group, whereas OPG levels were markedly increased in both treatment groups. d MicroCT analysis showed the reduction of trabecular bone volume in femurs of OVX mice. e-h TC administration significantly improved BMD, Tb.Th, BV/TV, and Tb.N. compared to untreated OVX mice. i, j Histological analysis showed decreased trabecular bone volume (yellow boxed area) in femurs of OVX mice compared to sham mice. TC treatment elevated trabecular bone volume in OVX mice. k TRAP staining showed that Oc.S/BS was markedly decreased after TC and ZO treatment compared to the OVX group. Results are presented as mean ± SD. Scale bar 0.2 mm. *p \ 0.05 cumulative dosage of zoledronate, but not 99 Tc-MDP, may be associated with the occurrence of BRONJ in mice undergoing dental extraction.
It has been proved that nitrogen-containing bisphosphates, e.g., zoledronate, are capable of modulating both innate and adaptive immune responses [22, 23] . Importantly, cumulative high dosage of zoledronate can affect the Th17/ Treg ratio, thus causing BRONJ-like disease in mice [7] . Therefore, to clarify whether 99 Tc-MDP treatment alters the Treg/Th17 ratio, we examined the levels of Tregs and Th17 cells in the spleens of mice at 2 weeks after tooth extraction. Zoledronate only and zoledronate/Dex-treated mice showed a significantly decreased level of CD4
? CD25 ? Foxp3 ? cells (Tregs) and an increased level of CD4
? IL17 ? cells (Th17) in spleen cells compared with untreated control (Fig. 4a) . However, 99 Tc-MDP-treated groups, with or without Dex, neither significantly decreased the level of Tregs nor increased Th17 levels (Fig. 4a) . Consequently, the ratio of Tregs/Th17 was markedly decreased in the zoledronate alone and zoledronate/Dex-treated group compared with the control and 99 Tc-MDP-treated groups (Fig. 4b) . These findings suggest that 99 Tc-MDP has less risk of causing BRONJ onset in the mouse model at the dosage of 125 lg/kg compared with the zoledronate-treated group.
Discussion
To date, bisphosphonates are the most widely used antiresorptive drugs for osteoporosis. However, BRONJ has become a major concern of bisphosphonate use [1, [6] [7] [8] . Although the etiology of BRONJ remains unclear, it is 
IL17
? cells (Th17) in spleen cells from ZO onlyand ZO? Dex-treated mice compared with the untreated control and TC groups. b The Treg/Th17 ratio in spleens of C57BL/6J mice after receiving TC treatment was significantly higher than that with ZO treatment. Results are representative of three independent experiments. *p \ 0.05 believed that the pathogenesis results, in part, from suppression of the adaptive Tregs and activation of Th17 cells in newly established BRONJ-like disease models [7, 24] . In order to characterize a novel bisphosphonate derivative, 99 Tc-MDP, we treated osteoporotic mice with it and assessed whether it could induce BRONJ. Our data suggest that 99 Tc-MDP ameliorates OVX-induced osteoporosis, with effects comparable to zoledronate. Importantly, since 99 Tc-MDP does not alter the levels of Th17 cells or Tregs, it does not cause BRONJ-like disease in a mouse model. OVX mice are a reliable animal model for estrogen deficiency-induced osteoporosis [2, 12, 16, 17] . Since 8-week-old mice show comparable bone turnover markers with older adult mice [25] , they have been used as an OVX mouse model in previous studies [14, 26, 27] . It is well established that osteoclastogenesis is a main cause in estrogen deficiency-induced osteoporosis [3, 4, 16] , and evidence shows that impairment of the osteoblast lineage also contributes to the osteoporotic phenotype in OVX mice [12, 15, 28] . In addition to the established understanding of the inhibition of osteoclast activity by bisphosphonates, recent studies have shown that bisphosphonates also stimulate osteoblast function [29] . In this study, we demonstrate that both 99 Tc-MDP and zoledronate inhibit bone resorption in OVX mice and affect MSC functions, including inhibition of CFU-F numbers, proliferation rate, and adipogenic differentiation but enhancement of osteogenic differentiation, which is in accordance with previous studies [29, 30] . However, the significant differences between the sham group and the drug-treated OVX groups indicate that the drugs can only partly rescue the deficiency of MSC functions in the OVX model by promoting osteogenic commitment and sacrificing their proliferation and adipogenic differentiation. Therefore, 99 Tc-MDP, as a bisphosphonate derivative, may share the same cellular mechanism of inhibiting bone resorption, while stimulating MSC/osteoblast function.
ELISA indicated that both 99 Tc-MDP and zoledronate administration markedly decreased RANKL levels in serum, whereas increased OPG levels compared with OVX group in short-term treatment, which is in accordance with a previous study in rats [31] . However, it has been proved that long-term bisphosphonate treatment reduces bone turnover, thereby resulting in increased risk of subtrochanteric femoral fractures in osteoporosis patients [32, 33] . These discrepant results may due to, at least in part, the length of the bisphosphonate treatment period and intraspecimen variations. Therefore, the long-term effects of 99 Tc-MDP and zoledronate on the mouse model of OVX still await further studies. Among the many potential risk factors, Treg/Th17 cells are important immune components contributing to BRONJ onset in animal models [7] . Tregs can suppress various immune responses and thus regulate immune homeostasis [34] . Tregs can also suppress IL-17-producing Th17 cells, which play important roles in several autoimmune diseases, including RA, systemic lupus erythematosus or multiple sclerosis [35] [36] [37] . Using a newly developed BRONJ mouse model, we confirmed that zoledronate administration could inhibit Tregs and activate Th17 cells, thereby causing BRONJ-like lesions at the site induced by dental extraction. Since most BRONJ patients are also bisphosphonate-treated cancer patients who take immunosuppressant drugs, including Dex, we tested the addition of Dex and found that zoledronate-induced BRONJ-like lesions were enhanced. Since 99 Tc-MDP has immunomodulatory properties manifested by downregulation of proinflammatory cytokines, including TNF-a and IL1-b, ICAM-1, and MMPs [9, 10] Over the decades, 99m Tc-MDP has been used as a radioactive imaging agent for bone scintigraphy.
99 Tc-MDP, used in this study, has no radioactivity and is harmless to the human body in long-term clinical treatment of systemic inflammatory diseases such as RA [9] . 99 Tc-MDP may not be toxic to mice, as no impairment was observed in bladder, kidney, and liver. It is important to evaluate the long-term effect of multidose administration of 99 Tc-MDP and elucidate the mechanism by which 99 Tc-MDP differs from other bisphosphonates in the context of the Treg/Th17 ratio. To the best of our knowledge, this is the first study to show that 99 Tc-MDP is equipotent as zoledronate to prevent OVXinduced bone loss, with minimal risks of causing BRONJ. However, whether 99 Tc-MDP is effective for the treatment of bone loss in other diseases awaits further study.
In summary, we found that administration of Tc-MDP therapy may be a promising approach in the treatment of osteoporosis-associated bone resorption with less risk of causing BRONJ.
